XML 79 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets, Net (Tables)
 9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table provides a summary of the activity in goodwill by segment for the nine month period ended September 30, 2019 (in thousands):
 
Consumer
Health
 
Prescription
Pharmaceuticals
 
Total
Balances at December 31, 2018
$
16,717

 
$
267,162

 
$
283,879

Currency translation adjustments
—

 
(1
)
 
(1
)
Acquisitions
—

 
—

 
—

Impairments
—

 
(15,955
)
 
(15,955
)
Dispositions
—

 
—

 
—

Balances at September 30, 2019
$
16,717

 
$
251,206

 
$
267,923
Schedule of Other Intangible Assets
The following table sets forth the major categories of the Company’s intangible assets as of September 30, 2019 and December 31, 2018, and the weighted average remaining amortization period as of September 30, 2019 and December 31, 2018 (dollar amounts in thousands):
 
Gross
Amount (2)
 
Accumulated
Amortization
 
Reclassifications
 
Impairment (1)
 
Net
Balance
 
Wtd Avg Remaining
Amortization Period
(years)
September 30, 2019
 
 
 
 
 
 
 
 
 
 
 
Product licensing rights
$
472,041

 
$
(227,678
)
 
$
—

 
$
(15,550
)
 
$
228,813

 
8.6
IPR&D
4,400

 
—

 
—

 
—

 
4,400

 
N/A - Indefinite lived
Trademarks
16,000

 
(6,999
)
 
—

 
—

 
9,001

 
17.2
Customer relationships
4,225

 
(2,513
)
 
—

 
—

 
1,712

 
6.6
Other intangibles
6,000

 
(6,000
)
 
—

 
—

 
—

 
0.0
 
502,666

 
$
(243,190
)
 
$
—

 
$
(15,550
)
 
$
243,926

 
 
December 31, 2018
 

 
 

 
 
 
 
 
 

 
 
Product licensing rights
$
597,960

 
$
(203,323
)
 
$
5,300

 
$
(131,306
)
 
$
268,631

 
9.2
IPR&D
149,161

 
—

 
(5,300
)
 
(139,461
)
 
4,400

 
N/A - Indefinite lived
Trademarks
16,000

 
(6,304
)
 
—

 
—

 
9,696

 
17.5
Customer relationships
4,225

 
(2,318
)
 
—

 
—

 
1,907

 
7.3
Other intangibles
11,235

 
(5,658
)
 
—

 
(5,235
)
 
342

 
0.3
 
$
778,581

 
$
(217,603
)
 
$
—

 
$
(276,002
)
 
$
284,976

 
 

(1) Impairment of product licensing rights is stated at gross carrying cost of $15.6 million less accumulated amortization of $4.9 million as of the impairment date. Accordingly, the total net impairment expense was $10.7 million, for the nine month period ended September 30, 2019.

(2) Differences in the Gross Amounts between periods are due to the write down of fully amortized assets and additions during the period.